动物造模,2型糖尿病 z-bio 2021-10-18 403

　　Objective: To discuss the effectiveness and feasibility of vaccine immune intervention against insulin resistance with human RBP-4 as the target, and to provide basic research data for the advancement of new treatments for type 2 diabetes.

　　Method: A vaccine expressing human RBP-4 with T7 phage as a vector was used to subcutaneously immunize type 2 diabetic mice. At the same time, an empty vector group and a blank control group were set up. After two immunizations, the degree of humoral immunity and fasting blood glucose were measured at different time points. Value and body weight, and the animals were sacrificed at 20 weeks to stop pathological section detection.

　　Results: The RBP-4 vaccine effectively induced the production of anti-RBP-4 IgG antibodies, and reached the peak at 12 weeks. At the same time, the fasting blood glucose level of the immunized group gradually decreased from the 8th week, to the empty carrier group at the 12th week. There is a significant difference from the blank group, and has been maintained below the incidence value of type 2 diabetes (7 mmol/L). During the experiment, the type 2 diabetic mice showed no obvious abnormalities such as curling up, erect hair, nose scratching, convulsions, etc., and no obvious lesions were observed in the heart, liver, spleen, lung, and kidney tissues of the mice in the immune group and the empty carrier group, indicating RBP. -4 The vaccine is safe.

　　Conclusion: RBP-4 vaccine can significantly reduce blood sugar in type 2 diabetic mice, and may become a new breaking point in the treatment of insulin resistance.